Evidence map›Paper›PMID 33708956›Full record

ArticleAnnals of translational medicine2021

The effect of primary site, functional status and treatment modality on survival in gastroenteropancreatic neuroendocrine neoplasms with synchronous liver metastasis: a US population-based study.

Ning Pu, Joseph R Habib, Michael Bejjani, Hanlin Yin, Minako Nagai, Jianan Chen, Benedict Kinny-Köster, Qiangda Chen, Jicheng Zhang, Jun Yu and 2 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. [Liver metastases of neuroendocrine tumors].Chirurgie (Heidelberg, Germany) · 2022
    Review
  4. Article
  5. Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021
    Review
  6. Primary tumor location (rightTherapeutic advances in gastroenterology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 3 countries.

Ning PuDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Joseph R HabibDepartment of Surgery, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Michael BejjaniDepartment of Gastroenterology and Hepatology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Hanlin YinDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Minako NagaiDepartment of Surgery, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jianan ChenDepartment of Surgery, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Benedict Kinny-KösterDepartment of Surgery, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Qiangda ChenDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Jicheng ZhangDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Jun YuDepartment of Surgery, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Wenchuan WuDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Wenhui LouDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Cancer Research Center · USJohns Hopkins Medicine · USJohns Hopkins University · USZhongshan Hospital · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNFudan University · CNSun Yat-sen University · CNThe First Affiliated Hospital, Sun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe incidence of indolent gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) has increased dramatically. GEP-NENs often present late with concomitant liver metastasis, which is associated with poorer outcomes.

methodsThis is a retrospective cohort study of 3,188 patients with liver metastatic GEP-NENs from the national scale Surveillance, Epidemiology, and End Results (SEER) database in the USA between 2010 and 2016. The population-based sample of GEP-NENs with liver metastasis was stratified by primary site (intestinal, pancreatic or gastric), surgical intervention and functional status.

resultsOf the 3,188 patients with liver metastatic GEP-NENs in this study, intestinal NENs (iNENs) were the most common and displayed the best 5-year survival of 42.6% compared to 25.8% in pancreatic NENs (pNENs) and 12.0% in gastric NENs (gNENs). Surgical intervention [hazard ratio (HR): 0.46, 95% CI: (0.40-0.53), P<0.001] and carcinoid subtype showed robust survival advantages across all groups. pNENs with liver metastasis were associated with the greatest benefit of surgery [HR: 0.55, 95% CI: (0.41-0.75), P<0.001] while iNENs were the most commonly treated by surgery. After risk adjustment, primary site was not associated with outcome in the non-surgical group.

conclusionsTaken collectively, when diagnosed with liver metastasis, iNENs conferred a better overall prognosis than both pNENs and gNENs. Primary surgical resection, especially of carcinoid type tumors, emerged as a robust prognostic indicator of better outcomes irrespective of primary site. This finding was most pronounced in liver metastatic pNENs. When possible, we recommend surgical intervention in GEP-NENs with liver metastasis.

Indexed as

functional statusGastroenteropancreatic neuroendocrine neoplasm (GEP-NEN)primary siteprognosissurgical intervention

Identifiers

PMID33708956
PMCPMC7944286
OpenAlexW3124405831

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.